Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

Completed · Phase 1/Phase 2

Conditions studied: Melanoma

In brief

The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.

Key facts

Study ID

NCT00257465

Run by

AVAX Technologies

People needed

82

Starts

2005-06-01

Expected to finish

2008-06-01

Last updated by the study team

2015-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• stage III or IV melanoma at least one tumor mass of at least 2.5 cm diameter that can be excised to make vaccine good performance status

You may not qualify if…

• brain metastases need for steroids or other immunosuppressive drugs positive PPD tests positive test for HIV, hepatitis B (antigen), or hepatitis C other serious medical illnesses

Where it is running

• University of Arizona Cancer Center — Tucson, Arizona, United States
• Pacific Oncology and Hematology Associates — San Diego, California, United States
• University of Illinois School of Medicine — Chicago, Illinois, United States
• University of Louisville — Louisville, Kentucky, United States
• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.